1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Morepen Laboratories Limited

Morepen Laboratories Limited

MOREPENLAB.BO
Morepen Laboratories LimitedIN flagBombay Stock Exchange
60.78
INR
+1.79
- -
33.25BMarket Cap
Morepen Laboratories Limited
MOREPENLAB.BO
(Bombay Stock Exchange)

Recent

price

60.78

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
5.08
6.43
7.25
8.16
8.91
10.78
13.04
13.29
16.81
18.67
26.13
34.26
28.15
32.91
33.77
32.93
32.91
Revenue per Share
-1.04
-0.53
-0.46
-0.06
0.05
0.28
0.53
0.66
0.64
0.75
2.16
2.26
0.77
1.88
2.2
1.73
1.73
Basic EPS, GAAP
0.17
0.53
0.64
0.64
1.02
0.89
0.69
0.81
0.12
-0.13
0.23
-2.84
-2.73
-0.16
-3.4
-2.33
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.2
- -
Dividend per Share
2.25
1.73
1.3
1.24
1.03
-1.51
-0.99
-0.33
0.31
1.06
3.21
5.49
5.82
7.6
9.58
2
2
Book Value per Share
5.88
5.38
4.92
4.85
4.64
2.09
2.6
2.96
3.64
4.47
7.31
10.5
12.99
14.73
19.39
20.57
20.56
Tangible Book Value per Share
450
450
450
450
450
450
450
450
450
450
450
450
502
511
536
548
549
Basic Weighted Avg Shares
2,283
2,893
3,259
3,668
4,006
4,851
5,864
5,978
7,562
8,396
11,754
15,416
14,140
16,821
18,116
18,057
18,057
Sales/Revenue/Turnover
-18.57
-9.96
-3.71
0.88
2.59
5.65
4.69
5.09
3.65
3.76
7.51
7.07
3.65
7.44
8.01
4.94
4.94
Operating Margin (%)
482
481
458
458
387
352
339
343
399
369
303
276
279
335
290
364
364
Depreciation Expense
-469
-236
-205
-28
21
128
236
296
288
336
971
1,017
387
962
1,180
949
949
Net Income, GAAP
- -
- -
- -
- -
6.02
- -
- -
- -
1.15
14.14
1.44
19.75
30.63
28.65
23.91
20.24
20.24
Effective Tax Rate (%)
-20.56
-8.17
-6.3
-0.76
0.53
2.64
4.03
4.95
3.81
4
8.26
6.6
2.74
5.72
6.51
5.25
5.25
Profit Margin (%)
-228
-153
-116
-118
-133
-1,289
-1,329
-967
-397
207
1,230
2,778
4,350
4,870
6,587
6,733
6,733
Working Capital
1,287
1,139
946
748
623
511
14
29
18
9
8
13
9
34
392
1,379
1,379
LT Debt
3,436
3,200
2,994
2,967
2,871
1,726
1,956
2,255
2,526
2,836
4,243
5,781
7,524
8,472
11,870
12,471
12,471
Total Equity
- -
- -
- -
- -
2.69
- -
11.12
12.54
10.75
9.6
23.62
16.91
5.22
10.8
10.18
5.18
5.18
Return on Invested Capital (%)
- -
- -
- -
- -
8.51
- -
598.36
2,164.31
247.22
81.12
88.72
48.63
13.76
26.79
23.31
22.16
22.16
Return on Capital (%)
-30.19
-26.43
-30.13
-4.85
4.2
- -
- -
- -
- -
109.25
101.06
51.94
14.35
28.26
26.16
30.44
30.44
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
1,327
- -
700
LT Borrowings
199
- -
1,336
LT Finance Leases
59
- -
43
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
548
- -
548
Market Capitalization
26,446
22,722
18,547

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
10,370
- -
11,636
Cash, Cash Equivalents & STI
933
- -
1,077
Accounts Receivable, Net
2,735
- -
3,331
Inventories
2,721
- -
2,718
Total Current Liabilities
4,644
- -
4,903
Payables & Accruals
- -
- -
- -
ST Debt
1,327
- -
700
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
22.67%
24.84%
5.07%
Free Cash Flow
17.68%
149.62%
-29.79%
Net Income, GAAP
40.74%
18.9%
-19.61%
Sales/Revenue/Turnover
14.96%
9.85%
-0.32%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4,010
4,218
4,446
4,148
16,821
2025
4,552
4,377
4,528
4,659
18,116
2026
4,252
4,116
4,842
4,847
18,057

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.29
0.42
0.63
- -
1.88
2025
0.71
0.65
0.49
0.35
2.2
2026
0.2
0.75
0.5
0.28
1.73

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
0.2
Similar Companies
CanaFarma Hemp Products Corp. (CNFHF)
JW Pharmaceutical Corporation (001060.KS)
Jinghua Pharmaceutical Group Co., Ltd. (002349.SZ)
Argent BioPharma Limited (RGT.AX)
Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd (000766.SZ)
Vivesto AB (VIVE.ST)
Business
Morepen Laboratories Limited (MOREPENLAB.BO) is an integrated pharmaceutical company engaged in the research, development, manufacturing, and marketing of active pharmaceutical ingredients (APIs), formulations, diagnostics, and home healthcare products. The company offers a diverse portfolio of products including generic drugs across therapeutic categories such as cardiovascular, anti-diabetic, anti-infective, gastroenterology, and central nervous system; diagnostic kits and devices for blood glucose monitoring, rapid tests, and clinical chemistry; over-the-counter (OTC) brands like Dr. Morepen for glucose meters, strips, vitamins, sanitizers, and personal care items; and APIs including Losartan Potassium, Valsartan, and Atorvastatin Calcium. It operates primarily in India with exports to over 50 countries across Asia, Africa, Latin America, Europe, and North America, serving institutional buyers, retailers, hospitals, and consumers. Founded in 1984 and headquartered in New Delhi, India, the company maintains manufacturing facilities in Baroda, Gujarat, and Dewas, Madhya Pradesh. In recent developments, Morepen Laboratories reported strong financial growth with consolidated net profit surging 92% to INR 207 crore for FY24, driven by robust domestic and export demand; expanded its diagnostic offerings with new launches in rapid testing and home healthcare devices; and strengthened its API business through capacity enhancements and strategic export partnerships in regulated markets.